[go: up one dir, main page]

NO20062098L - Faststofftilstandmontelukast - Google Patents

Faststofftilstandmontelukast

Info

Publication number
NO20062098L
NO20062098L NO20062098A NO20062098A NO20062098L NO 20062098 L NO20062098 L NO 20062098L NO 20062098 A NO20062098 A NO 20062098A NO 20062098 A NO20062098 A NO 20062098A NO 20062098 L NO20062098 L NO 20062098L
Authority
NO
Norway
Prior art keywords
compound
formula
faststofftilstandmontelukast
formulated
precipitation
Prior art date
Application number
NO20062098A
Other languages
English (en)
Inventor
Dennie Johan Marijn Van Heuvel
Arjanne Overeem
Original Assignee
Synthon Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34520017&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20062098(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Synthon Bv filed Critical Synthon Bv
Publication of NO20062098L publication Critical patent/NO20062098L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

En faststofform av en forbindelse av formel (1) er tilveiebrakt. Forbindelsen av formel (1) kan oppnås i faststofftilstand ved utfelling fra en løsning som inneholder det samme. Forbindelsen er nyttig som leukotrien antagonist og kan formuleres til en farmasøytisk sammensetning som også inkluderer en farmasøytisk akseptabel eksipient.
NO20062098A 2003-10-10 2006-05-10 Faststofftilstandmontelukast NO20062098L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50995703P 2003-10-10 2003-10-10
PCT/EP2004/011430 WO2005040123A1 (en) 2003-10-10 2004-10-08 Solid-state montelukast

Publications (1)

Publication Number Publication Date
NO20062098L true NO20062098L (no) 2006-05-10

Family

ID=34520017

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20062098A NO20062098L (no) 2003-10-10 2006-05-10 Faststofftilstandmontelukast

Country Status (12)

Country Link
US (1) US7553853B2 (no)
EP (1) EP1678139B1 (no)
JP (2) JP2007508271A (no)
AT (1) ATE522507T1 (no)
AU (1) AU2004283832B2 (no)
CA (1) CA2541994A1 (no)
ES (1) ES2371549T3 (no)
IL (1) IL174758A (no)
NO (1) NO20062098L (no)
PT (1) PT1678139E (no)
WO (1) WO2005040123A1 (no)
ZA (1) ZA200602837B (no)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050107612A1 (en) * 2002-12-30 2005-05-19 Dr. Reddy's Laboratories Limited Process for preparation of montelukast and its salts
AU2004283832B2 (en) 2003-10-10 2011-04-07 Synthon B.V. Solid-state montelukast
US20070225325A1 (en) * 2004-01-28 2007-09-27 Pliva-Istrazivanje I Razvoj D.O.O. Solid Forms of Montelukast Acid
WO2005074935A1 (en) * 2004-01-30 2005-08-18 Teva Pharmaceutical Industries Ltd. Montelukast free acid polymorphs
EP1709002A2 (en) * 2004-01-30 2006-10-11 Teva Pharmaceutical Industries Ltd. Montelukast sodium polymorphs
EP1760077A1 (en) * 2004-01-30 2007-03-07 Teva Pharmaceutical Industries Ltd. Montelukast free acid polymorphs
JP2007520546A (ja) * 2004-02-03 2007-07-26 ケマジス リミティド モンテルカストナトリウムの安定な非晶質性形態
EP1646612B1 (en) 2004-04-21 2009-07-01 Teva Pharmaceutical Industries Ltd Processes for preparing montelukast sodium
US7501517B2 (en) * 2004-04-30 2009-03-10 Synthon Ip, Inc. Process for making montelukast and intermediates therefor
US7829716B2 (en) * 2004-04-30 2010-11-09 Synthon Pharmaceuticals, Inc. Process for making montelukast and intermediates therefor
US20090143590A1 (en) * 2004-07-19 2009-06-04 Matrix Laboratories Ltd. Process for the Preparation of Montelukast and its Salts
US9149472B2 (en) * 2004-08-31 2015-10-06 Jack William Schultz Controlled release compositions for treatment of cognitive, emotional and mental ailments and disorders
EP1817289A1 (en) * 2004-11-30 2007-08-15 Medichem, S.A. New process for the preparation of a leukotriene antagonist
WO2006064269A2 (en) * 2004-12-17 2006-06-22 Cipla Limited Salts of leukotriene antagonist montelukast
JP2008510840A (ja) * 2005-07-05 2008-04-10 テバ ファーマシューティカル インダストリーズ リミティド モンテルカストの精製
AR057909A1 (es) * 2005-11-18 2007-12-26 Synthon Bv Proceso para preparar montelukast y compuestos relacionados, que utiliza un compuesto intermediario derivado de un ester sulfonico.
US8178680B2 (en) * 2005-12-13 2012-05-15 Msn Laboratories Limited Process for the preparation of Montelukast and its pharmaceutically acceptable salts
EP1803457A1 (en) * 2005-12-30 2007-07-04 Krka Tovarna Zdravil, D.D., Novo Mesto Pharmaceutical composition containing montelukast
EP1976522B2 (en) * 2005-12-30 2019-07-03 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition containing montelukast
JP2009526047A (ja) * 2006-02-09 2009-07-16 テバ ファーマシューティカル インダストリーズ リミティド モンテルカストナトリウムの安定な医薬製剤
WO2007107297A1 (en) * 2006-03-17 2007-09-27 Synthon B.V. Montelukast amantadine salt
EP1886998A1 (en) * 2006-08-09 2008-02-13 Esteve Quimica, S.A. Purification process of montelukast and its amine salts
SI22382A (sl) * 2006-10-26 2008-04-30 Krka, Tovarna Zdravil, D.D., Novo Mesto Nov postopek za pripravo montelukasta
US8115004B2 (en) * 2006-11-20 2012-02-14 Msn Laboratories Limited Process for pure montelukast sodium through pure intermediates as well as amine salts
US20080188664A1 (en) * 2007-01-15 2008-08-07 Chemagis Ltd. Process for preparing montelukast sodium containing controlled levels of impurities
RU2470639C2 (ru) * 2007-10-25 2012-12-27 Мерк Фросст Кэнада Лтд. Композиции для ингаляции, содержащие кислоту монтелукаст и ингибитор pde-4 или ингаляционный кортикостероид
WO2009098271A1 (en) * 2008-02-06 2009-08-13 Farmaprojects, S.A. Process for the purification of montelukast by the preparation of acid addition salts and tert-amylamine salt
CN102046602A (zh) * 2008-04-25 2011-05-04 斯索恩有限公司 制备孟鲁司特中间体的方法
EP2287154A1 (en) 2009-07-14 2011-02-23 KRKA, D.D., Novo Mesto Efficient synthesis for the preparation of montelukast
BR112012015923A2 (pt) 2010-02-26 2020-09-08 Toray Industries, Inc. "preparação sólida revestida"
WO2011121091A1 (en) 2010-03-31 2011-10-06 Krka, D.D., Novo Mesto Efficient synthesis for the preparation of montelukast and novel crystalline form of intermediates therein
US8471030B2 (en) 2010-12-06 2013-06-25 Orochem Technologies Inc. Purification of montelukast using simulated moving bed
EP3134076A4 (en) 2014-04-25 2017-12-20 R.P. Scherer Technologies, LLC A stable montelukast solution
EP3846792A4 (en) 2018-09-06 2022-10-12 Innopharmascreen Inc. METHODS AND COMPOSITIONS FOR TREATING ASTHMA OR PARKINSON'S DISEASE
US10828254B2 (en) 2018-09-28 2020-11-10 Intelgenx Corp. Oral film formulation for modulating absorption profile
CN111307979A (zh) * 2020-03-14 2020-06-19 鲁南制药集团股份有限公司 一种孟鲁司特钠及其制剂的有关物质检测方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2053216C (en) * 1990-10-12 2003-04-08 Michel L. Belley Saturated hydroxyalkylquinoline acids as leukotriene antagonists
DK0480717T3 (da) * 1990-10-12 1999-02-08 Merck Frosst Canada Inc Umættede hydroxyalkylquinolinsyrer som leukotrienantagonister
US5565473A (en) 1990-10-12 1996-10-15 Merck Frosst Canada, Inc. Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists
US5856322A (en) 1990-10-12 1999-01-05 Merck Frosst Canada, Inc. Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists
US5266568A (en) 1990-10-12 1993-11-30 Merck Frosst Canada, Inc. Hydroxyalkylquinoline ether acids as leukotriene antagonists
US5270324A (en) 1992-04-10 1993-12-14 Merck Frosst Canada, Inc. Fluorinated hydroxyalkylquinoline acids as leukotriene antagonists
TW448160B (en) 1993-12-28 2001-08-01 Merck & Co Inc Novel dicyclohexylamine salt and process for the preparation of leukotriene antagonists
GB9423511D0 (en) 1994-11-22 1995-01-11 Glaxo Wellcome Inc Compositions
US5585115A (en) 1995-01-09 1996-12-17 Edward H. Mendell Co., Inc. Pharmaceutical excipient having improved compressability
US5523477A (en) 1995-01-23 1996-06-04 Merck & Co., Inc. Process for the preparation of 1-(thiomethyl)-cyclopropaneacetic acid
US5869673A (en) 1997-02-28 1999-02-09 Merck & Co., Inc. Process for 3-(2-(7-chloro-2-quinolinyl)ethenyl) - benzaldehyde
US6224907B1 (en) * 1998-03-06 2001-05-01 Alza Corporation Anti-asthma therapy
WO2002034741A2 (en) * 2000-10-20 2002-05-02 Eli Lilly And Company A NOVEL CRYSTALLINE FORM OF 6-HYDROXY-3-(4-[2-(PIPERIDIN-1-YL)ETHOXY]PHENOXY)-2-(4-METHOXYPHENYL)BENZO[b]THIOPHENE HYDROCHLORIDE
CN1420113A (zh) * 2001-11-16 2003-05-28 北京上地新世纪生物医药研究所 孟鲁司特钠的制备方法及其制备中间体
CN1171873C (zh) * 2001-12-26 2004-10-20 北京上地新世纪生物医药研究所 一种孟鲁司特钠的制备方法及其制备中间体
AU2003209043A1 (en) * 2002-02-07 2003-09-02 Dr. Reddy's Laboratories Ltd. Novel anhydrous amorphous forms of montelukast sodium salt
US20050107612A1 (en) 2002-12-30 2005-05-19 Dr. Reddy's Laboratories Limited Process for preparation of montelukast and its salts
US20040265375A1 (en) 2003-04-16 2004-12-30 Platteeuw Johannes J. Orally disintegrating tablets
US8450491B2 (en) 2003-06-06 2013-05-28 Morepen Laboratories Limited Method for the preparation of montelukast acid and sodium salt thereof in amorphous form
AU2004283832B2 (en) 2003-10-10 2011-04-07 Synthon B.V. Solid-state montelukast
WO2005074935A1 (en) 2004-01-30 2005-08-18 Teva Pharmaceutical Industries Ltd. Montelukast free acid polymorphs
US7189853B2 (en) 2004-04-15 2007-03-13 Dr. Reddy's Laboratories Limited Process for the preparation of [R-(E)-1-[[[1-[3-[2-[7-chloro-2-quinolinyl]ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]cyclopropaneacetic acid (Montelukast) and its pharmaceutically acceptable salts
US7829716B2 (en) 2004-04-30 2010-11-09 Synthon Pharmaceuticals, Inc. Process for making montelukast and intermediates therefor
US7501517B2 (en) 2004-04-30 2009-03-10 Synthon Ip, Inc. Process for making montelukast and intermediates therefor

Also Published As

Publication number Publication date
EP1678139A1 (en) 2006-07-12
AU2004283832B2 (en) 2011-04-07
US7553853B2 (en) 2009-06-30
CA2541994A1 (en) 2005-05-06
EP1678139B1 (en) 2011-08-31
US20050107426A1 (en) 2005-05-19
ATE522507T1 (de) 2011-09-15
JP2012072149A (ja) 2012-04-12
JP2007508271A (ja) 2007-04-05
AU2004283832A1 (en) 2005-05-06
ZA200602837B (en) 2007-09-26
ES2371549T3 (es) 2012-01-05
IL174758A (en) 2012-09-24
PT1678139E (pt) 2011-11-28
WO2005040123A1 (en) 2005-05-06
IL174758A0 (en) 2006-08-20

Similar Documents

Publication Publication Date Title
NO20062098L (no) Faststofftilstandmontelukast
TW200608972A (en) Aryl-pyridine derivatives
LUC00155I2 (no)
TW200738241A (en) Pyridazine derivatives
DE60336850D1 (en) Substituierte arylcyclopropylacetamide als glucokinaseaktivatoren
MX2010005824A (es) Derivados de aminotiazol.
BG106013A (en) New compounds and compositions as protease inhibitors
DE60217118D1 (de) 2-anilino-pyrimidin-derivate als cyclin-abhängige kinase hemmer
GEP20094676B (en) Piperidine compounds and pharmaceutical compositions containing them
EA200200938A1 (ru) Фармацевтические композиции, содержащие производные азетидина, новые производные азетидина и их получение
CA2510853A1 (en) Pyrrolopyrimidine derivatives
EA201000643A1 (ru) Замещенное производное этилендиамина для лечения микобактериальных заболеваний и фармацевтическая композиция на его основе
AUPR213700A0 (en) Antiviral agents
TW200616976A (en) Pyrimidine derivatives
EP1340755A4 (en) AGENT WITH EFFECT AGAINST HELICOBACTER
ATE374773T1 (de) Polycyclische verbindungen als potenten alpha2- adrenoceptor antagonisten
TW200616958A (en) New alkyl-pyridines as 11-beta inhibitors for diabetes
MX2009003169A (es) Derivados de sulfonamida.
MY135646A (en) Indolyl derivatives
UA90742C2 (en) Pyrazolone derivatives
GB0212410D0 (en) Organic compounds
WO2004048381A3 (en) Pyrazoloazepine compounds as pharmaceutical agents
HRP20060023A2 (en) Use of bicyclo[2.2.1]heptane derivatives for the preparation of neuroprotective pharmaceutical compositions
EA200500683A1 (ru) Новые соединения пирролидина и тиазолидина, способ их получения и фармацевтические композиции, которые их содержат
ECSP045086A (es) Composiciones farmaceuticas que contienen macrolidos

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application